Cladribine tablets regulatory update

FDA extended the PDUFA date for cladribine tablets from Merck by 3 months to Feb. 28, 2011, from Nov. 28. The NDA is under Priority Review to treat relapsing forms of multiple sclerosis. Merck resubmi...